ADR Biomedical
ADR Biomedical Holdings Inc.
Company highlights
The company has paid a dividend for 2 consecutive years.
Key figures
Period Apr 2025 to Mar 2026ConsolidatedJapanese GAAP
Company profile
Tables scroll sideways
Disclosed data
Business activities and revenue composition
Revenue and profit by business segment
Disclosed segments (business divisions used in reporting): one
Revenue and profit
ADR Biomedical
Period Apr 2025 to Mar 2026Source Annual securities reports
Amounts by account
| Group | Account | Amount | Consolidated / Non-consolidated |
|---|---|---|---|
| Selling, general and administrative expenses | Other | ¥0.2 billion | Consolidated |
| Commission fees | ¥0.2 billion | Consolidated | |
| Experiment and research expenses | ¥0.2 billion | Consolidated | |
| Provision of allowance for doubtful accounts | ¥0.1 billion | Consolidated | |
| Salaries and allowances | ¥0.1 billion | Consolidated | |
| Provision for shareholder benefit program | ¥43.73 million | Consolidated | |
| Profit by stage | Ordinary income | ¥-0.9 billion | Consolidated |
| Operating income | ¥-0.9 billion | Consolidated | |
| Net income | ¥-0.4 billion | Consolidated | |
| Gross profit (loss) | ¥10.56 million | Consolidated |
ADR Biomedical
Selling, general and administrative expenses
Period Apr 2025 to Mar 2026Source Annual securities reports
- Other ¥0.2 billion
- Commission fees ¥0.2 billion
- Experiment and research expenses ¥0.2 billion
- Provision of allowance for doubtful accounts ¥0.1 billion
- Salaries and allowances ¥0.1 billion
- Provision for shareholder benefit program ¥0.0 billion
Performance, financial position and capital allocation
Long-term changes in performance
ADR Biomedical
Long-term revenue, profit and asset trends
Period 2013 to 2026Source Annual securities reportsDisclosed
ADR Biomedical
Recent performance trends
Source Annual securities reports
Year-on-year comparison
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales | ¥1.3B | ¥2.1B | ¥1.6B | ¥0.1B | ¥0.1B |
| Year on year (%) | -3.8% | +60.6%◆ | -27.2%◆ | -92.2%◆ | -58.3%◆ |
| Ordinary income (loss) | -¥0.4B | -¥0.9B | -¥0.9B | -¥0.9B | -¥0.9B |
| Change from prior year | 0.56x | 2.06x | 1.05x | 0.95x | 1.07x |
| Ordinary income (loss) as a share of Net sales | -31.3% | -40.2% | -58.1% | -707.8% | -1,809.6% |
| Change (percentage points) | +22.4 points◆ | -8.9 points◆ | -17.9 points◆ | -649.7 points◆ | -1,101.9 points◆ |
Fiscal periods marked for changes
Earlier fiscal periods (9)
- 2014Net sales year on year +52.5%, Ordinary income (loss) as a share of revenue +11.2 points, Ordinary income (loss) loss to profit
- 2016Net sales year on year -34.1%, Ordinary income (loss) as a share of revenue -19.0 points, Ordinary income (loss) profit to loss
- 2017Ordinary income (loss) as a share of revenue -5.6 points
- 2018Net sales year on year -80.6%, Ordinary income (loss) as a share of revenue +39.2 points, Ordinary income (loss) loss to profit
- 2019Net sales year on year +268.6%, Ordinary income (loss) as a share of revenue -13.8 points
- 2020Net sales year on year -38.7%, Ordinary income (loss) as a share of revenue -26.3 points, Ordinary income (loss) profit to loss
- 2021Ordinary income (loss) as a share of revenue -38.0 points
- 2022Ordinary income (loss) as a share of revenue +22.4 points
- 2023Net sales year on year +60.6%, Ordinary income (loss) as a share of revenue -8.9 points
- 2024Net sales year on year -27.2%, Ordinary income (loss) as a share of revenue -17.9 points
- 2025Net sales year on year -92.2%, Ordinary income (loss) as a share of revenue -649.7 points
- 2026Net sales year on year -58.3%, Ordinary income (loss) as a share of revenue -1,101.9 points
ADR Biomedical
Earnings and net assets per share over time
Unit yenSource Annual securities reports
ADR Biomedical
Return on equity over time
Unit %Source Annual securities reports
Consolidated indicators (15 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥1.3 billion | ¥2.1 billion | ¥1.6 billion | ¥0.1 billion | ¥50.99 million |
| Ordinary income (loss) | ¥-0.4 billion | ¥-0.9 billion | ¥-0.9 billion | ¥-0.9 billion | ¥-0.9 billion |
| Net income (loss) attributable to owners of parent | ¥-77.63 million | ¥-1.1 billion | ¥0.1 billion | ¥-2.1 billion | ¥-0.4 billion |
| Comprehensive income | ¥-77.03 million | ¥-1.1 billion | ¥0.1 billion | ¥-2.1 billion | ¥-0.4 billion |
| Net assets | ¥3.7 billion | ¥2.7 billion | ¥2.8 billion | ¥0.6 billion | ¥22.02 million |
| Total assets | ¥16.0 billion | ¥14.1 billion | ¥5.8 billion | ¥3.5 billion | ¥0.4 billion |
| Net assets per share | 392.12 yen | 273.41 yen | 288.89 yen | 46.93 yen | 2.47 yen |
| Basic earnings (loss) per share | -8.79 yen | -118.71 yen | 15.47 yen | -239.7 yen | -44.46 yen |
| Diluted earnings per share | Could not be retrieved | Could not be retrieved | 15.42 yen | Could not be retrieved | Could not be retrieved |
| Equity-to-asset ratio | 21.9% | 17.3% | 44.3% | 11.8% | 6.0% |
| Return on equity | -2.3% | -35.6% | 5.5% | -142.8% | -180.0% |
| Net cash provided by (used in) operating activities | ¥-0.2 billion | ¥-39.52 million | ¥-1.2 billion | ¥-1.0 billion | ¥-0.8 billion |
| Net cash provided by (used in) investing activities | ¥-0.2 billion | ¥-0.3 billion | ¥8.7 billion | ¥22.90 million | ¥3.0 billion |
| Net cash provided by (used in) financing activities | ¥35.80 million | ¥0.3 billion | ¥-7.2 billion | ¥0.2 billion | ¥-2.3 billion |
| Cash and cash equivalents | ¥0.7 billion | ¥0.7 billion | ¥1.0 billion | ¥0.3 billion | ¥0.1 billion |
Parent only indicators (12 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | ¥0.2 billion | ¥0.5 billion | ¥0.6 billion | ¥0.2 billion | ¥0.1 billion |
| Ordinary income (loss) | ¥0.2 billion | ¥-0.2 billion | ¥-0.6 billion | ¥-2.8 billion | ¥-0.5 billion |
| Net income (loss) | ¥0.3 billion | ¥-0.7 billion | ¥-3.8 billion | ¥-3.2 billion | ¥0.1 billion |
| Capital stock | ¥0.1 billion | ¥0.1 billion | ¥0.1 billion | ¥0.1 billion | ¥0.1 billion |
| Total number of issued shares (common stock) | 8,929,419 shares | 8,929,419 shares | 8,929,419 shares | 8,929,419 shares | 8,929,419 shares |
| Net assets | ¥7.7 billion | ¥7.0 billion | ¥3.2 billion | ¥20.92 million | ¥-65.47 million |
| Total assets | ¥13.0 billion | ¥11.9 billion | ¥3.3 billion | ¥97.57 million | ¥0.4 billion |
| Net assets per share | 861.25 yen | 778.7 yen | 357.21 yen | 2.34 yen | -7.33 yen |
| Basic earnings (loss) per share | 30.61 yen | -82.54 yen | -421.48 yen | -354.86 yen | 14.02 yen |
| Diluted earnings per share | 30.39 yen | Could not be retrieved | Could not be retrieved | Could not be retrieved | Could not be retrieved |
| Equity-to-asset ratio | 57.7% | 56.5% | 90.4% | -195.3% | -18.5% |
| Return on equity | 3.8% | -10.4% | -77.4% | -227.3% | -97.8% |
Dividend history
| Fiscal year | Annual dividend per share | Of which interim | Payout ratio (as reported, parent only) | Flag |
|---|---|---|---|---|
| FY ending 3/2020 | ¥10 | Could not be retrieved | 21.0% | |
| FY ending 3/2019 | ¥20 | Could not be retrieved | 22.7% | |
| FY ending 3/2018 | ¥10 | Could not be retrieved | 15.1% | Stock split or share consolidation noted |
Shareholder composition
Share ownership by holder category
ADR Biomedical
Unit %Source Annual securities reports
- Financial institutions6.68%
- Securities firms14.58%
- Other corporations34.54%
- Foreign holders (institutions)0.09%
- Foreign holders (individuals)0.12%
- Individuals and others43.98%
- Government and municipalities0.00%
Major shareholders
| Rank | Shareholder | Shareholding ratio | Shares held |
|---|---|---|---|
| 1 | 株式会社HGキャピタル | 12.92% | 1,153,814 |
| 2 | 株式会社SBI証券 | 12.03% | 1,073,834 |
| 3 | 橋本 征道 | 11.85% | 1,058,295 |
| 4 | FTLキャピタルマネジメント株式会社 | 11.05% | 986,406 |
| 5 | 株式会社東京ウエルズ | 9.22% | 823,170 |
| 6 | 日本証券金融株式会社 | 6.65% | 594,000 |
| 7 | 堀江 聡寧 | 5.16% | 460,841 |
| 8 | 窪田 芳郎 | 4.21% | 376,236 |
| 9 | 杉山 力一 | 1.27% | 113,810 |
| 10 | 窪田 恵介 | 1.15% | 102,400 |
Research and development expenses and capital expenditure
| Fiscal year | Research and development |
|---|---|
| FY ending 3/2026 | ¥0.2 billion |
| FY ending 3/2025 | ¥0.2 billion |
Revenue scale in the same industry
ADR Biomedical
Source Annual securities reports of each company
Information and Communication: 642 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 NTTFY Mar 2026 ¥14.4T
- 2 SoftBank GroupFY Mar 2026 ¥7.8T
- 3 ソフトバンクFY Mar 2026 ¥7.0T
- … 635 companies
- 639 OKWEBFY Jun 2026 ¥0.3B
- 640 Quantum SolutionsFY Feb 2026 ¥0.3B
- 641 ADR BiomedicalThis companyFY Mar 2026 ¥50,988,000
- 642 HODL1FY Oct 2025 ¥26,550,000
Workforce information
Audit and disclosure information
| Item | Value |
|---|---|
| Audit firm | 佳生監査法人 |
| Audit fees (this year, total) | ¥20.50 million |
| Non-audit fees (this year, total) | ¥1.00 million |
| Going concern note | Note present |
| Accounting standard | Japanese GAAP |
Related books, articles and videos
Books that cover companies in the same industry
This company: not covered in the books below
Same industry: Information and Communication
“Kaisha no Shikumi: Selling the Same Hit Again and Again”
Reads the filings of game and film companies for how many years and in how many ways they resell the same title.
Information and Communication companies in this book: CAPCOM, TOHO, GungHo Online Entertainment
“Ano Kaisha no Shikumi” series, Vol.9 — Kindle and paperback
Find it on Amazon →
Same industry: Information and Communication
“Kaisha no Shikumi: Free”
Reads the filings of internet and broadcasting companies for who pays for services that users get free.
Information and Communication companies in this book: LY, Mercari, Nippon Television
“Ano Kaisha no Shikumi” series, Vol.6 — Kindle and paperback
Find it on Amazon →
Sources and methodology
Retrieved disclosed figures
Major management indicators (5 years) (25 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Comprehensive income | ¥-0.4 billion | Consolidated |
| Net cash provided by (used in) operating activities | ¥-0.8 billion | Consolidated |
| Net sales | ¥50.99 million | Consolidated |
| Net cash provided by (used in) investing activities | ¥3.0 billion | Consolidated |
| Cash and cash equivalents | ¥0.1 billion | Consolidated |
| Net assets | ¥22.02 million | Consolidated |
| Ordinary income (loss) | ¥-0.9 billion | Consolidated |
| Total assets | ¥0.4 billion | Consolidated |
| Return on equity | -180.0% | Consolidated |
| Equity-to-asset ratio | 6.0% | Consolidated |
| Net income (loss) attributable to owners of parent | ¥-0.4 billion | Consolidated |
| Net cash provided by (used in) financing activities | ¥-2.3 billion | Consolidated |
| Basic earnings (loss) per share | -44.46 yen | Consolidated |
| Net assets per share | 2.47 yen | Consolidated |
| Net sales | ¥0.1 billion | Parent only |
| Net income (loss) | ¥0.1 billion | Parent only |
| Total number of issued shares (common stock) | 8,929,419 shares | Parent only |
| Net assets | ¥-65.47 million | Parent only |
| Ordinary income (loss) | ¥-0.5 billion | Parent only |
| Total assets | ¥0.4 billion | Parent only |
| Return on equity | -97.8% | Parent only |
| Equity-to-asset ratio | -18.5% | Parent only |
| Capital stock | ¥0.1 billion | Parent only |
| Basic earnings (loss) per share | 14.02 yen | Parent only |
| Net assets per share | -7.33 yen | Parent only |
Employees (7 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of employees | 13 people | Consolidated |
| Number of employees | 13 people | Consolidated |
| Average length of service (years) | 7.8 years | Parent only |
| Average annual salary | ¥5.91 million | Parent only |
| Average age (years) | 51.67 years old | Parent only |
| Number of employees | 3 people | Parent only |
| Number of employees | 3 people | Parent only |
Shares (8 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Number of shares held | 6,742,806 shares | Consolidated |
| Total number of shares held treasury shares etc | 1,300 shares | Consolidated |
| Number of shares | 8,929,419 shares | Consolidated |
| Shareholding ratio treasury shares etc | 0.0% | Consolidated |
| Shareholding ratio | 75.5% | Consolidated |
| Number of shares held in own name treasury shares etc | 1,300 shares | Consolidated |
| Number of voting rights | 88,959 units | Consolidated |
| Total shareholder return | 56.5% | Parent only |
Other disclosed items (3 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Write-downs of inventories | ¥12.03 million | Consolidated |
| Number of consolidated subsidiaries | 8 companies | Consolidated |
| Total return on the share price index | 179.0% | Parent only |
Research and development (2 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | ¥0.2 billion | Consolidated |
| Research and development expenses | ¥0.2 billion | Consolidated |
Audit (4 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Fees for audit and attestation services - reporting company | ¥20.50 million | Consolidated |
| Fees for audit and attestation services - total | ¥20.50 million | Consolidated |
| Fees for non-audit services - reporting company | ¥1.00 million | Consolidated |
| Fees for non-audit services - total | ¥1.00 million | Consolidated |
Accounts unique to this company (4 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Revenue | ¥-73.33 million | Consolidated |
| Change in average annual salary from the previous year | -2.9% | Parent only |
| Revenue | ¥0.05 million | Parent only |
| Revenue | ¥0.2 billion | Parent only |
Balance sheet (75 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥7.30 million | Consolidated |
| Other | ¥11.04 million | Consolidated |
| Other | ¥23.44 million | Consolidated |
| Other, net | ¥0 | Consolidated |
| Retained earnings | ¥-3.0 billion | Consolidated |
| Prepaid expenses | ¥78.79 million | Consolidated |
| Merchandise | ¥59.07 million | Consolidated |
| Non-current liabilities | ¥0.1 billion | Consolidated |
| Non-current assets | ¥17.55 million | Consolidated |
| Accounts receivable - trade | ¥8.19 million | Consolidated |
| Contract liabilities | ¥2.61 million | Consolidated |
| Investments and other assets | ¥17.55 million | Consolidated |
| Investment securities | ¥10.25 million | Consolidated |
| Property, plant and equipment | ¥0 | Consolidated |
| Accounts receivable - other | ¥0.1 billion | Consolidated |
| Consumption taxes receivable | ¥41.29 million | Consolidated |
| Accrued consumption taxes | ¥53.69 million | Consolidated |
| Accrued expenses | ¥24.24 million | Consolidated |
| Accounts payable - other | ¥0.1 billion | Consolidated |
| Provision for shareholder benefit program | ¥24.67 million | Consolidated |
| Shareholders' equity | ¥22.02 million | Consolidated |
| Current liabilities | ¥0.2 billion | Consolidated |
| Current assets | ¥0.4 billion | Consolidated |
| Accumulated depreciation | ¥-0.1 billion | Consolidated |
| Cash and cash equivalents | ¥0.1 billion | Consolidated |
| Cash and deposits | ¥0.1 billion | Consolidated |
| Net assets | ¥22.02 million | Consolidated |
| Net assets | ¥22.02 million | Consolidated |
| Total assets | ¥0.4 billion | Consolidated |
| Deferred tax liabilities | ¥0.1 billion | Consolidated |
| Treasury stock | ¥-1.64 million | Consolidated |
| Liabilities | ¥0.3 billion | Consolidated |
| Liabilities and net assets | ¥0.4 billion | Consolidated |
| Supplies | ¥7.34 million | Consolidated |
| Accounts payable - trade | ¥1.65 million | Consolidated |
| Allowance for doubtful accounts | ¥-0.1 billion | Consolidated |
| Capital surplus | ¥2.9 billion | Consolidated |
| Capital stock | ¥0.1 billion | Consolidated |
| Net defined benefit liability | ¥11.85 million | Consolidated |
| Other | ¥7.30 million | Parent only |
| Other | ¥2.68 million | Parent only |
| Other | ¥42.08 million | Parent only |
| Other capital surplus | ¥3.1 billion | Parent only |
| Retained earnings | ¥-5.7 billion | Parent only |
| Legal retained earnings | ¥18.29 million | Parent only |
| Non-current liabilities | ¥11.33 million | Parent only |
| Non-current assets | ¥37.35 million | Parent only |
| Investments and other assets | ¥37.35 million | Parent only |
| Investment securities | ¥10.00 million | Parent only |
| Accrued expenses | ¥26.60 million | Parent only |
| Accounts payable - other | ¥0.1 billion | Parent only |
| Provision for shareholder benefit program | ¥24.67 million | Parent only |
| Shareholders' equity | ¥-65.47 million | Parent only |
| Current liabilities | ¥0.4 billion | Parent only |
| Current assets | ¥0.3 billion | Parent only |
| Cash and deposits | ¥0.1 billion | Parent only |
| Advances paid | ¥17.74 million | Parent only |
| Net assets | ¥-65.47 million | Parent only |
| Net assets | ¥-65.47 million | Parent only |
| Total assets | ¥0.4 billion | Parent only |
| Retained earnings brought forward | ¥-5.8 billion | Parent only |
| Treasury stock | ¥-1.64 million | Parent only |
| Liabilities | ¥0.4 billion | Parent only |
| Liabilities and net assets | ¥0.4 billion | Parent only |
| Allowance for doubtful accounts | ¥-0.3 billion | Parent only |
| Allowance for doubtful accounts | ¥-2.6 billion | Parent only |
| Capital surplus | ¥5.6 billion | Parent only |
| Legal capital surplus | ¥2.4 billion | Parent only |
| Capital stock | ¥0.1 billion | Parent only |
| Provision for retirement benefits | ¥11.33 million | Parent only |
| Accounts receivable from subsidiaries and affiliates trade | ¥27.86 million | Parent only |
| Shares of subsidiaries and associates | ¥20.00 million | Parent only |
| Affiliated company short-term loans payable | ¥0.2 billion | Parent only |
| Loans receivable to subsidiaries and affiliates | ¥2.7 billion | Parent only |
| Long-term receivables affiliates | ¥0.3 billion | Parent only |
Statement of income (71 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥0.13 million | Consolidated |
| Other | ¥0.45 million | Consolidated |
| Other | ¥0.2 billion | Consolidated |
| Gain on forgiveness of debts | ¥0.4 billion | Consolidated |
| Comprehensive income | ¥-0.4 billion | Consolidated |
| Income before dividends distribution from silent partnership income taxes | ¥-0.3 billion | Consolidated |
| Dividend distribution from silent partnerships | ¥68.95 million | Consolidated |
| Interest and dividend income | ¥0.79 million | Consolidated |
| Guaranty money income | ¥2.91 million | Consolidated |
| Operating income | ¥-0.9 billion | Consolidated |
| Non-operating income | ¥5.42 million | Consolidated |
| Non-operating expenses | ¥21.93 million | Consolidated |
| Net cash provided by (used in) operating activities | ¥-0.8 billion | Consolidated |
| Cost of sales | ¥40.43 million | Consolidated |
| Gross profit (loss) | ¥10.56 million | Consolidated |
| Net sales | ¥50.99 million | Consolidated |
| Net income | ¥-0.4 billion | Consolidated |
| Net income | ¥-0.4 billion | Consolidated |
| Net income (loss) | ¥-0.4 billion | Consolidated |
| Net income (loss) | ¥-0.4 billion | Consolidated |
| Net cash provided by (used in) investing activities | ¥3.0 billion | Consolidated |
| Interest expenses | ¥18.48 million | Consolidated |
| Commission fees | ¥0.2 billion | Consolidated |
| Gain on reversal of share acquisition rights | ¥0.2 billion | Consolidated |
| Provision for shareholder benefit program | ¥43.73 million | Consolidated |
| Income taxes - current | ¥1.85 million | Consolidated |
| Income taxes | ¥-0.95 million | Consolidated |
| Income taxes - deferred | ¥-2.80 million | Consolidated |
| Impairment loss | ¥20.63 million | Consolidated |
| Foreign exchange losses | ¥2.99 million | Consolidated |
| Extraordinary income | ¥0.6 billion | Consolidated |
| Extraordinary loss | ¥20.63 million | Consolidated |
| Effect of exchange rate change on cash and cash equivalents | ¥-2.99 million | Consolidated |
| Net increase (decrease) in cash and cash equivalents | ¥-0.1 billion | Consolidated |
| Income (loss) before income taxes | ¥-0.4 billion | Consolidated |
| Income (loss) before income taxes | ¥-0.4 billion | Consolidated |
| Ordinary income | ¥-0.9 billion | Consolidated |
| Salaries and allowances | ¥0.1 billion | Consolidated |
| Purchase of treasury stock | ¥-0.10 million | Consolidated |
| Subsidy income | ¥4.50 million | Consolidated |
| Comprehensive income attributable to owners of parent | ¥-0.4 billion | Consolidated |
| Experiment and research expenses | ¥0.2 billion | Consolidated |
| Net cash provided by (used in) financing activities | ¥-2.3 billion | Consolidated |
| Selling, general and administrative expenses | ¥0.9 billion | Consolidated |
| Provision of allowance for doubtful accounts | ¥0.1 billion | Consolidated |
| Other | ¥95.20 million | Parent only |
| Gain on forgiveness of debts | ¥0.4 billion | Parent only |
| Interest income | ¥0.23 million | Parent only |
| Operating income | ¥-0.5 billion | Parent only |
| Non-operating income | ¥8.13 million | Parent only |
| Non-operating expenses | ¥9.94 million | Parent only |
| Gross profit (loss) | ¥0.1 billion | Parent only |
| Net sales | ¥0.1 billion | Parent only |
| Net income (loss) | ¥0.1 billion | Parent only |
| Net income (loss) | ¥0.1 billion | Parent only |
| Interest expenses | ¥6.95 million | Parent only |
| Commission fees | ¥0.2 billion | Parent only |
| Gain on reversal of share acquisition rights | ¥0.2 billion | Parent only |
| Provision for shareholder benefit program | ¥43.73 million | Parent only |
| Income taxes - current | ¥1.21 million | Parent only |
| Income taxes | ¥1.21 million | Parent only |
| Impairment loss | ¥10.51 million | Parent only |
| Foreign exchange losses | ¥2.99 million | Parent only |
| Extraordinary income | ¥0.6 billion | Parent only |
| Extraordinary loss | ¥10.51 million | Parent only |
| Income (loss) before income taxes | ¥0.1 billion | Parent only |
| Ordinary income | ¥-0.5 billion | Parent only |
| Purchase of treasury stock | ¥-0.10 million | Parent only |
| Selling, general and administrative expenses | ¥0.6 billion | Parent only |
| Reversal of allowance for doubtful accounts | ¥7.90 million | Parent only |
| Provision of allowance for doubtful accounts | ¥12.87 million | Parent only |
Statement of changes in equity (4 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Total changes during the period | ¥-0.6 billion | Consolidated |
| Net changes in items other than shareholders' equity | ¥-0.2 billion | Consolidated |
| Total changes during the period | ¥-86.39 million | Parent only |
| Net changes in items other than shareholders' equity | ¥-0.2 billion | Parent only |
Statement of cash flows (30 items)
| Item | Value | Consolidated / Non-consolidated |
|---|---|---|
| Other | ¥58.33 million | Consolidated |
| Other | ¥0.26 million | Consolidated |
| Other | ¥-0.10 million | Consolidated |
| Increase decrease in notes and accounts payable trade | ¥1.37 million | Consolidated |
| Gain on forgiveness of debts | ¥-0.4 billion | Consolidated |
| Collection of investments in capital | ¥10.10 million | Consolidated |
| Interest expenses paid | ¥-22.30 million | Consolidated |
| Interest and dividends income received | ¥0.79 million | Consolidated |
| Decrease (increase) in advance payments to suppliers | ¥0.1 billion | Consolidated |
| Interest and dividend income | ¥-0.79 million | Consolidated |
| Decrease increase in notes and accounts receivable trade | ¥-5.90 million | Consolidated |
| Subtotal | ¥-0.7 billion | Consolidated |
| Purchase of investment securities | ¥-10.00 million | Consolidated |
| Interest expenses | ¥18.48 million | Consolidated |
| Proceeds from refund of leasehold deposits | ¥35.00 million | Consolidated |
| Gain on reversal of share acquisition rights | ¥-0.2 billion | Consolidated |
| Proceeds from sales of property plant and equipment | ¥2.9 billion | Consolidated |
| (Increase) decrease in accounts receivables other | ¥-0.1 billion | Consolidated |
| Decrease/increase in consumption taxes receivable/payable | ¥69.44 million | Consolidated |
| Increase (decrease) in reserve for shareholder special benefit | ¥-13.78 million | Consolidated |
| Decrease (increase) in inventories | ¥-13.73 million | Consolidated |
| Income taxes refund (paid) | ¥-18.31 million | Consolidated |
| Depreciation | ¥0.69 million | Consolidated |
| Impairment loss | ¥20.63 million | Consolidated |
| Foreign exchange loss (gain) | ¥2.99 million | Consolidated |
| Increase in short term loans payable | ¥0.4 billion | Consolidated |
| Decrease in short term loans payable | ¥-0.3 billion | Consolidated |
| Increase (decrease) in allowance for doubtful accounts | ¥0.1 billion | Consolidated |
| Increase (decrease) in net defined benefit liability | ¥0.71 million | Consolidated |
| Repayment of long term loans payable | ¥-2.3 billion | Consolidated |
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Net cash provided by (used in) operating activities | ¥-0.8 billion | Consolidated | Disclosed |
| Number of employees | 13 | Consolidated | Disclosed |
| Net assets | ¥22.02 million | Consolidated | Disclosed |
| Net sales | ¥50.99 million | Consolidated | Disclosed |
| Operating income | ¥-0.9 billion | Consolidated | Disclosed |
| Ordinary income | ¥-0.9 billion | Consolidated | Disclosed |
| Net income | ¥-0.4 billion | Consolidated | Disclosed |
| Total assets | ¥0.4 billion | Consolidated | Disclosed |
| Operating margin | -1777.2% | Consolidated | Calculated |
| Net margin | -778.4% | Consolidated | Calculated |
| Sales per employee | 3922154 yen | Consolidated | Calculated |
| Total asset turnover | 0.14 times | Consolidated | Calculated |
| Net assets to total assets | 6.0% | Consolidated | Calculated |